Nanotechnology-based non-invasive strategies in ocular therapeutics: Approaches, limitations to clinical translation, and safety concerns
Contact Lens and Anterior Eye,
Journal Year:
2025,
Volume and Issue:
unknown, P. 102367 - 102367
Published: Jan. 1, 2025
Language: Английский
Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy
Biomedicine & Pharmacotherapy,
Journal Year:
2025,
Volume and Issue:
185, P. 117962 - 117962
Published: March 11, 2025
Language: Английский
Impact of sterilization method on the system performance of lipid-based novel drug delivery
International Journal of Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
unknown, P. 125486 - 125486
Published: March 1, 2025
Language: Английский
Melatonin loaded nanostructured lipid carriers for the treatment of uveal melanoma
Journal of Drug Delivery Science and Technology,
Journal Year:
2024,
Volume and Issue:
100, P. 106057 - 106057
Published: Aug. 10, 2024
Uveal
melanoma,
a
highly
aggressive
intraocular
tumor
and
the
second
most
common
form
of
ocular
malignancy,
currently
lacks
effective
therapeutic
options.
Therefore,
this
study
addresses
an
unmet
medical
need
by
developing
nanostructured
lipid
carriers
(NLC)
as
potential
delivery
system
for
melatonin
(MEL)
to
target
uveal
melanoma.
NLC
were
optimized
ophthalmic
administration
addition
cationic
surfactant
increase
mucoadhesivity
negatively
charged
surface.
MEL-loaded
(MEL-NLC)
exhibited
suitable
particle
size
(<200
nm),
good
colloidal
stability
(5
months),
sustained
MEL
release.
In
vitro
cytotoxicity
assays
demonstrated
antiproliferative
activity
against
melanoma
cells
while
maintaining
corneal
cell
viability,
further
confirmed
in
HET-CAM
test
vivo
tolerance
studies.
Additionally,
inflammation
studies
performed
since
constitutes
one
main
hallmarks
cancer
development
progression.
Consequently,
MEL-NLC
displayed
anti-inflammatory
properties.
Furthermore,
preliminary
biodistribution
results
suggested
their
ability
reach
posterior
segment
eye,
mainly
retina
ciliary
body,
positioning
them
promising
strategy
treatment.
Language: Английский
Combination of Apigenin and Melatonin with nanostructured lipid carriers as anti-inflammatory ocular treatment
International Journal of Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
unknown, P. 125160 - 125160
Published: Dec. 1, 2024
Ocular
inflammation
is
a
complex
pathology
with
limited
treatment
options.
While
traditional
therapies
have
side
effects,
novel
approaches,
such
as
natural
compounds
like
Apigenin
(APG)
and
Melatonin
(MEL)
offer
promising
solutions.
APG
MEL,
in
combination
nanostructured
lipid
carriers
(NLC),
may
provide
synergistic
effect
treating
ocular
inflammation,
potentially
improving
patient
outcomes
reducing
adverse
effects.
NLC
could
chemical
protection
of
these
compounds,
while
offering
sustained
release
into
the
surface.
Optimized
exhibited
suitable
physicochemical
parameters,
physical
stability,
were
biocompatible
vitro
corneal
cell
line,
ovo
by
using
hen's
egg
chorioallantoic
membrane
test.
In
vivo
studies
confirmed
NLCs'
ability
to
attenuate
interleukin-6
(IL-6),
IL-8
monocyte
chemoattractant
protein
1
(MCP-1)
cytokine
levels
decreasing
rabbit
model.
These
findings
suggest
that
co-encapsulation
MEL
represent
strategy
for
managing
inflammatory
conditions.
Language: Английский